You are here



Biotech company Transbiomed and Barcelona’s Vall d'Hebron Research Institute have developed a new diagnostic tool for early detection of prostate cancer.


Over the past 12 years, Dr. Jordi Monés has dedicated his work to treating and researching macular degeneration, diabetic retinopathy, macular disease and vitreoretinal microsurgery.


Only two other of these machines are currently in use: one in Zurich, and one at the Memorial Sloan-Kettering Cancer Center, in New York.


New knowledge regarding the genetic and molecular make-up of diseases and developments in information and imaging technology is changing the face of biomedical and clinical research.